Economic burden and the cost-effectiveness of treatment of cardiovascular diseases in Africa

Heart

Volumn 94, Issue 2, 2008, Pages 140-144

  Gaziano, Thomas A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; BENZATHINE PENICILLIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRINOLYTIC AGENT; GENERIC DRUG; HEMOGLOBIN A1C; HEPARIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLUENZA VACCINE; METOPROLOL; PENICILLIN G; SATURATED FATTY ACID; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR; VEGETABLE OIL;

ACUTE HEART INFARCTION; ADD ON THERAPY; AFRICA; AGING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CONGESTIVE HEART FAILURE; CORONARY ARTERY BYPASS GRAFT; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DISABILITY; GLYCEMIC CONTROL; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH ECONOMICS; HEART FAILURE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INFLUENZA; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; OBESITY; POPULATION RESEARCH; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; PRODUCTIVITY; REVIEW; RHEUMATIC HEART DISEASE; RISK REDUCTION; SALT INTAKE; SCREENING; SECONDARY PREVENTION; SINGLE DRUG DOSE; SMOKING CESSATION; STROKE; UNITED STATES; VALVULAR HEART DISEASE; ADULT; AGED; COST BENEFIT ANALYSIS; COST OF ILLNESS; ECONOMICS; HEALTH CARE POLICY; HEALTH PROMOTION; MIDDLE AGED; QUALITY ADJUSTED LIFE YEAR; RISK FACTOR;

ADULT; AFRICA; AGED; CARDIOVASCULAR DISEASES; COST OF ILLNESS; COST-BENEFIT ANALYSIS; HEALTH POLICY; HEALTH PROMOTION; HUMANS; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS; SODIUM CHLORIDE, DIETARY;

EID: 38749148099     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2007.128785     Document Type: Review

References (37)

1. Murray CJ, Lopez AD. The Global Burden of Disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Cambridge: Harvard University, 1996.
2. Lopez A, Mathers C, Ezzati M, et al. Global Burden of Disease and Risk Factors. Washington, DC: Oxford University Press and World Bank, 2006.
3. World Bank. World Development Indicators. Washington, DC: The World Bank, 2002.
4. Pestana JA, Steyn K, Leiman A, et al. The direct and indirect costs of cardiovascular disease in South Africa in 1991. S Afr Med J 1996;86:679-84.
5. American Heart Association. Heart Disease and Stroke Statistics - 2004 Update. Dallas,TX: American Heart Association, 2003.
6. Gaziano TA. Cardiovascular disease in the developing world and its cost-effective management. Circulation 2005;112:3547-53.
7. Kochar A. Ill-health, savings and portfolio choices in developing countries. Journal of Developing Economics 2004;73:257-85.
8. Leeder S, Raymond S, Greenberg H, et al. A Race Against Time: The Challenge of Cardiovascular Disease in Developing Countries. New York: Trustees of Columbia University, 2004.
9. WHO. Preventing chronic diseases: a vital investment: WHO global report. Geneva: World Health Organization, 2005.
10. Jamison D, Breman J, Measham A, et al. Disease Control Priorities in Developing Countries. 2nd edn. New York: Oxford University Press and The World Bank, 2006.
11. Murray C, Lauer J, Hutubessy R, et al. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. Lancet 2003;361:717-25.
12. Willet W, Koplan J, Nugent R, et al. Prevention of Chronic Disease by Diet and Lifestyle Changes. In: Jamison D, ed. Disease Control Priorities in Developing Countries. Oxford: Oxford University Press, 2006.
13. Gaziano TA, Steyn K, Cohen DJ, et al. Cost-effectiveness analysis of hypertension guidelines in South Africa: absolute risk versus blood pressure level. Circulation 2005;112:3569-76.
14. Intersalt Cooperative Research Group. Intersalt: an international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excretion. BMJ 1988;297:319-28.
15. Midgley JP, Matthew AG, Greenwood CM, et al. Effect of reduced dietary sodium on blood pressure: a meta-analysis of randomized controlled trials. JAMA 1996;275:1590-7.
16. Cutler JA, Follmann D, Allender PS. Randomized trials of sodium reduction: an overview. Am J Clin Nutr 1997;65(2 Suppl):643S-651S.
17. Elliot P, Stamler J, Nichols R, et al. Intersalt Cooperative Research Group. Intersalt revisited: further analyses of 24 hour sodium excretion and blood pressure within and across populations. BMJ 1996;312:1249-53.
18. Jha P, Chaloupka FJ, Moore J, et al. Tobacco Addiction. In: Jamison D, et al, eds. Disease Control Priorities in Developing Countries. 2nd edn. New York: Oxford University Press and The World Bank, 2006:869-85.
19. Willett WC, Ascherio A. Trans fatty acids: are the effects only marginal? Am J Public Health 1994;84:722-4.
20. Zatonski WA, McMichael AJ, Powles JW. Ecological study of reasons for sharp decline in mortality from ischaemic heart disease in Poland since 1991. BMJ 1998;316:1047-51.
21. Oomen CM, Ocke MC, Feskens EJ, et al. Association between trans fatty acid intake and 10-year risk of coronary heart disease in the Zutphen Elderly Study: a prospective population-based study. Lancet 2001;357:746-51.
22. Tosteson AN, Weinstein MC, Hunink MG, et al. Cost-effectiveness of populationwide educational approaches to reduce serum cholesterol levels. Circulation 1997;95:24-30.
23. Lemogoum D, Seedat YK, Mabadeje AF, et al. Recommendations for prevention, diagnosis and management of hypertension and cardiovascular risk factors in sub-Saharan Africa. J Hypertens 2003;21:1993-2000.
24. Puska P, Kansanterveyslaboratorio (Finland), World Health Organization Regional Office for Europe. Community control of cardiovascular diseases: evaluation of a comprehensive community programme for control of cardiovascular diseases in North Karelia, Finland, 1972-1977.Copenhagen: Published on behalf of the National Public Health Laboratory of Finland by the World Health Organization, Regional Office for Europe, 1981.
25. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13.
26. Rodgers A, Lawes C, Gaziano T, et al. The Growing Burden of Risk from High Blood Pressure, Cholesterol, and Bodyweight. In: Jamison D, ed. Disease Control Priorities in Developing Countries. New York: Oxford University Press and the World Bank, 2006.
27. Hypertension Society of Southern Africa, endorsed by the Medical Association of South Africa and the Medical Research Council. Guidelines for the management of hypertension at primary health care level. S Afr Med J 1995;85:1321-5.
28. Rossouw JE, Jooste PL, Chalton DO, et al. Community-based intervention: the Coronary Risk Factor Study (CORIS). Int J Epidemiol 1993;22:428-38.
29. Gaziano T, Reddy KS, Paccaud F, et al. "Cardiovascular Disease". In: Jamison D, et al, eds. Disease Control Priorities in Developing Countries. 2nd edn. New York: Oxford University Press and The World Bank, 2006:645-62.
30. Mayosi BM. Contemporary trends in the epidemiology and management of cardiomyopathy and pericarditis in sub-Saharan Africa. Heart 2007;93:1176-83.
31. Gaziano TA, Opie LH, Weinstein MC. Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet 2006;368:679-86.
32. Chandra V, Pandav R, Laxminarayan R, et al. Neurological Disorders. In: Jamison D, et al, eds. Disease Control Priorities in Developing Countries. 2nd edn. New York: Oxford University Press and The World Bank, 2006:627-43.
33. Nayaran KV, Zhang P, Kanaya AM, et al. Diabetes: The pandemic and potential solutions. In: Jamison D, et al, eds. Disease Control Priorities in Developing Countries. Washington: Oxford University Press and The World Bank, 2006:591-603.
34. Strasser T. Cost-effective control of rheumatic fever in the community. Health Policy 1985;5:159-64.
35. Carapetis JR, Steer AC, Mulholland EK, et al. The global burden of group A streptococcal diseases. Lancet Infect Dis 2005;5:685-94.
36. Van Howe RS, Kusnier LP 2nd. Diagnosis and management of pharyngitis in a pediatric population based on cost-effectiveness and projected health outcomes. Pediatrics 2006;117:609-19.
37. Robertson KA, Volmink JA, Mayosi BM. Antibiotics for the primary prevention of acute rheumatic fever: a meta-analysis. BMC Cardiovasc Disord 2005;5:11.